June 9, 2008 - Aureon Laboratories, Inc. announced a collaborative research effort with Dr. Ignacio Wistuba, associate professor of pathology at The University of Texas M. D. Anderson Cancer Center. The goal of the study will be to quantitate and evaluate biomarkers that are associated with progression of disease and overall survival. The project will apply Aureon’s systems pathology platform for the analysis of tissues from approximately 350 non-small cell lung cancer (NSCLC) patients.Aureon’s systems pathology platform applies morphometric imaging to formalin-fixed, paraffin-embedded (FFPE) tissue specimens, enabling quantitation and integration of histological attributes and multiplexed protein biomarkers on a cell-by-cell basis. Additionally, Aureon has developed a multivariate algorithm that integrates histological, molecular, and clinical features to establish a comprehensive biometric signature associated with patient outcome. This approach allows for an analysis of histological and molecular information extracted from intact tissue specimens resulting in the identification of phenotypes associated with disease course... Aureon Laboratories' Press Release -
